Zobrazeno 1 - 10
of 268
pro vyhledávání: '"Tapan M. Kadia"'
Autor:
Zeev Estrov, Nitin Jain, Elias Jabbour, Srdan Verstovsek, Guillermo Garcia-Manero, Sherry Pierce, Farhad Ravandi, Uday R. Popat, Marina Konopleva, Xuelin Huang, Naval Daver, Naveen Pemmaraju, Hagop M. Kantarjian, Xuemei Wang, Gautam Borthakur, Caitlin R. Rausch, Alessandra Ferrajoli, Tapan M. Kadia, Jan A. Burger, Rashmi Kanagal-Shamanna, Courtney D. DiNardo
Publikováno v:
American Journal of Hematology. 96:914-924
Background The treatment of older patients with newly diagnosed acute myeloid leukemia (AML) using intensive chemotherapy is associated with treatment intolerance and poor survival. We evaluated two new lower-intensity regimens with clofarabine (n=11
Autor:
Zeev Estrov, Prithviraj Bose, Varsha Gandhi, Jan A. Burger, Xuemei Wang, Naveen Garg, Rashmi Kanagal-Shamanna, Naveen Pemmaraju, Philip A. Thompson, Ana Ayala, Hagop M. Kantarjian, Koji Sasaki, Keyur P. Patel, Tapan M. Kadia, Alessandra Ferrajoli, Susan O'Brien, Elias Jabbour, Gautam Borthakur, Koichi Takahashi, Marina Konopleva, Wanda Lopez, Michael J. Keating, Wei Wang, William G. Wierda, Nitin Jain, Jeffrey L. Jorgensen, William Plunkett, Sa Wang
Publikováno v:
Leukemia. 35:3421-3429
Chemoimmunotherapy with combined fludarabine, cyclophosphamide and rituximab (FCR) has been an effective treatment for patients with chronic lymphocytic leukemia (CLL). We initiated a phase II trial for previously untreated patients with CLL with mut
Autor:
Ken Furudate, Keyur P. Patel, Tomoyuki Tanaka, Jairo Matthews, Xingzhi Song, Jianhua Zhang, Guowen Liu, Kyle J. MacBeth, Courtney D. DiNardo, Yuanqing Yan, Bin Wu, Hagop M. Kantarjian, Koichi Takahashi, Latasha Little, Kapil N. Bhalla, Guillermo Garcia-Manero, Kiyomi Morita, Elias J. Jabbour, Tapan M. Kadia, Marina Konopleva, Erika Thompson, Curtis Gumbs, Mark G. Frattini, P. Andrew Futreal, Farhad Ravandi, Feng Wang
Publikováno v:
Nature Communications, Vol 12, Iss 1, Pp 1-13 (2021)
Allosteric inhibitors of mutant IDH1 or IDH2 induce terminal differentiation of the mutant leukemic blasts and provide durable clinical responses in approximately 40% of acute myeloid leukemia (AML) patients with the mutations. However, primary resis
Autor:
Marina Konopleva, Farhad Ravandi, Prithviraj Bose, Koichi Takahashi, Naval Daver, Kiran Naqvi, Srdan Verstovsek, Guillermo Garcia-Manero, Courtney D. DiNardo, Keyur P. Patel, Carlos E. Bueso-Ramos, Gautam Borthakur, Joseph D. Khoury, Guillermo Montalban-Bravo, Hagop M. Kantarjian, Koji Sasaki, Elias J. Jabbour, Tapan M. Kadia, Zeev Estrov, Sherry Pierce, Rashmi Kanagal-Shamanna, Kelly A. Soltysiak, Lucia Masarova, Sanam Loghavi, Naveen Pemmaraju
Publikováno v:
Cancer. 127:3113-3124
Background There are limited data on the clonal mechanisms underlying leukemogenesis, prognostic factors, and optimal therapy for atypical chronic myeloid leukemia (aCML). Methods The authors evaluated the clinicopathologic features, outcomes, and re
Autor:
Patrick W. Burke, Stephen M Clark, Marissa Olson, Tapan M. Kadia, Dale L. Bixby, Carissa Treptow, Shawn Griffin, Bernard L. Marini, Kelley L Ratermann, Caitlin R. Rausch, Lydia L. Benitez, Mallory Crain, Anthony J. Perissinotti, Kristen Pettit, Michael Filtz, Jeff Klaus
Publikováno v:
Leukemia & Lymphoma. 62:2184-2192
Liposomal daunorubicin/cytarabine (CPX-351) gained FDA approval for secondary AML after demonstrating improved outcomes over daunorubicin and cytarabine (7 + 3). A number of study limitations prompted a comparison of safety/efficacy of CPX-351 agains
Autor:
Elias Jabbour, Gautam Borthakur, Nicholas J. Short, Farhad Ravandi, Hagop M. Kantarjian, Courtney D. DiNardo, Koji Sasaki, Tapan M. Kadia
Publikováno v:
Cancer. 127:2049-2061
Background Several important treatment and supportive care strategies have been implemented over the past 4 decades in the management of acute myeloid leukemia (AML). Methods The authors identified 29,107 patients who were diagnosed with de novo AML
Publikováno v:
Cancer. 127:1186-1207
The unraveling of the pathophysiology of acute myeloid leukemia (AML) has resulted in rapid translation of the information into clinical practice. After more than 40 years of slow progress in AML research, the US Food and Drug Administration has appr
Autor:
Sa A. Wang, Farhad Ravandi, Sherry Pierce, Musa Yilmaz, Koichi Takahashi, Marina Konopleva, Tomoyuki Tanaka, Nicholas J. Short, L. Jeffrey Medeiros, Sanam Loghavi, Courtney D. DiNardo, Ken Furudate, Keyur P. Patel, Noushin Farnoud, Joseph D. Khoury, Hagop M. Kantarjian, Naval Daver, Tapan M. Kadia, Rashmi Kanagal-Shamanna, Jeffrey L. Jorgensen
Publikováno v:
Br J Haematol
Clonal haematopoiesis (CH) in patients with acute myeloid leukaemia (AML) may persist beyond attaining complete remission. From a consecutive cohort of 67 patients with nucleophosmin 1-mutated (NPM1mut ) AML, we identified 50 who achieved NPM1mut cle
Autor:
Nitin Jain, Courtney D. DiNardo, Sherry Pierce, Tapan M. Kadia, Farhad Ravandi, Elias Jabbour, Gautam Borthakur, Nadya Jammal, Xuemei Wang, Naval Daver, Guillermo Garcia-Manero, Alessandra Ferrajoli, Michael Andreeff, Kiran Naqvi, Sa A. Wang, Hagop M. Kantarjian, Zeev Estrov, Jorge E. Cortes, Naveen Pemmaraju, Iman Abou Dalle, Sarah Gwen Pelletier
Publikováno v:
Cancer. 127:1894-1900
Background New drug combinations have led to significant improvements in remission rates for patients with acute myeloid leukemia (AML). However, many patients with high-risk AML who respond to their initial treatment and are not candidates for allog
Autor:
Sherry Pierce, Christopher Kim, Bhakti Mehta, Gautam Borthakur, Nicholas J. Short, Aaron J. Katz, Naval Daver, Zhao Yang, Hagop M. Kantarjian, Jorge E. Cortes, Michael A. Kelsh, Yesid Alvarado, Elias Jabbour, Tapan M. Kadia, Farhad Ravandi, Guillermo Garcia-Manero, Richard Williams, Courtney D. DiNardo
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 20:e871-e882
Background Prognosis of patients with relapsed or refractory AML has been poor as no standard salvage therapy exists. Most trials of investigational agents begin in r/r AML and accrue a wide range of patients with different characteristics. Historica